AR058212A1 - Formas novedosas de acido (r-(r*, r* ))-2-(4-fluorofenil) - beta , delta- dihidroxi -5- (1- metiletil) -3-fenil-4- ( fenilamino) carbonil)-1h- pirrol -1- heptanoico magnesio - Google Patents

Formas novedosas de acido (r-(r*, r* ))-2-(4-fluorofenil) - beta , delta- dihidroxi -5- (1- metiletil) -3-fenil-4- ( fenilamino) carbonil)-1h- pirrol -1- heptanoico magnesio

Info

Publication number
AR058212A1
AR058212A1 ARP060105094A ARP060105094A AR058212A1 AR 058212 A1 AR058212 A1 AR 058212A1 AR P060105094 A ARP060105094 A AR P060105094A AR P060105094 A ARP060105094 A AR P060105094A AR 058212 A1 AR058212 A1 AR 058212A1
Authority
AR
Argentina
Prior art keywords
methylety
heptanoico
fluorophenil
dihydroxi
pirrol
Prior art date
Application number
ARP060105094A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37836758&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058212(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR058212A1 publication Critical patent/AR058212A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Se describen formas novedosas de sal magnesio de atorvastatina denominadas Forma A, Forma B, Forma C, Forma D, Forma E y Forma F, composiciones farmacéuticas que contienen tales compuestos, procedimientos para su preparacion y procedimientos que utilizan los compuestos para el tratamiento de hiperlipidemia, hipercolesterolemia, osteoporosis, hiperplasia prostática benigna (HPB) y enfermedad de Alzheimer. Reivindicacion 1: Una atorvastatina magnesio Forma A que tiene una difraccion de cristales finos por rayos X que contiene los siguientes valores de 2? medidos usando radiacion CuKalfa:9,3, 14,3 y 18,4.
ARP060105094A 2005-11-21 2006-11-21 Formas novedosas de acido (r-(r*, r* ))-2-(4-fluorofenil) - beta , delta- dihidroxi -5- (1- metiletil) -3-fenil-4- ( fenilamino) carbonil)-1h- pirrol -1- heptanoico magnesio AR058212A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73844705P 2005-11-21 2005-11-21

Publications (1)

Publication Number Publication Date
AR058212A1 true AR058212A1 (es) 2008-01-23

Family

ID=37836758

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105094A AR058212A1 (es) 2005-11-21 2006-11-21 Formas novedosas de acido (r-(r*, r* ))-2-(4-fluorofenil) - beta , delta- dihidroxi -5- (1- metiletil) -3-fenil-4- ( fenilamino) carbonil)-1h- pirrol -1- heptanoico magnesio

Country Status (10)

Country Link
US (3) US8084488B2 (es)
JP (1) JP2007137885A (es)
AR (1) AR058212A1 (es)
AT (1) ATE466840T1 (es)
DE (1) DE602006014193D1 (es)
DK (1) DK1957452T3 (es)
ES (1) ES2304335T3 (es)
PT (1) PT1957452E (es)
TW (1) TW200738624A (es)
WO (1) WO2007057755A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172452A1 (en) * 2005-05-03 2010-04-07 Ranbaxy Laboratories Limited Preparation of crystalline atorvastatin magnesium
US20100168201A1 (en) * 2005-11-29 2010-07-01 Biocan Limited Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Magnesium Salt (2:1)
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
WO2008125412A1 (en) * 2007-04-13 2008-10-23 Nicox S.A. Crystalline forms of atorvastatin 4-(nitrooxy) butyl ester
WO2009063476A1 (en) * 2007-11-16 2009-05-22 Biocon Limited A crystalline form of atorvastatin hemi magnesium salt and a process thereof
EP2130819A3 (en) 2008-04-10 2009-12-23 Ranbaxy Laboratories Limited Crystalline forms of atorvastatin magnesium
WO2009157005A1 (en) * 2008-06-26 2009-12-30 Biocon Limited Crystalline forms of atorvastatin hemi-magnesium salt and a process thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5342942A (en) 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
JP3254219B2 (ja) 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
PL193479B1 (pl) 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
DK0915866T3 (da) 1996-07-29 2002-06-10 Warner Lambert Co Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre
JP2001526256A (ja) 1997-12-19 2001-12-18 ワーナー−ランバート・エクスポート・リミテッド １，３−ジオールの合成方法
US5959156A (en) * 1998-11-12 1999-09-28 Bp Amoco Corporation Preparation of polyoxymethylene dimethyl ethers by catalytic conversion of dimethyl ether with formaldehyde formed by oxy-dehydrogenation of dimethyl ether
IN191236B (es) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US20040063969A1 (en) 1999-10-18 2004-04-01 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
PT1535613E (pt) 1999-11-17 2010-10-04 Teva Pharma Processo de preparação de uma forma polimórfica de atorvastatina de cálcio
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
CN1535139A (zh) 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
NZ526022A (en) 2000-11-16 2005-04-29 Teva Pharma Hydrolysis of [R(R*,R )]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
PL365312A1 (en) 2000-12-27 2004-12-27 Teva Pharmaceutical Industries Ltd Crystalline forms of atorvastatin
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (es) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
KR100609371B1 (ko) 2001-06-29 2006-08-08 워너-램버트 캄파니 엘엘씨 Ｒ-(ｒ*,ｒ*)-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-페닐아미노)카르보닐-1ｈ-피롤-1-헵탄산 칼슘염 (2:1) (아토르바스타틴)의 결정질 형태
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
UA77990C2 (en) 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
KR20040101229A (ko) 2002-02-14 2004-12-02 랜박시 래보러터리스 리미티드 알칼리 금속 첨가에 의해 안정화된 아토르바스타틴 배합물
CN100406436C (zh) 2002-02-15 2008-07-30 特瓦制药工业有限公司 阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法
CA2491051A1 (en) 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
HUE029911T2 (en) * 2004-07-16 2017-04-28 Lek Pharmaceuticals Products of atorvastatin calcium oxidative degradation
US20090208539A1 (en) 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
WO2006070248A1 (en) * 2004-12-28 2006-07-06 Ranbaxy Laboratories Limited Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
WO2006084474A2 (en) * 2005-02-10 2006-08-17 Lifecycle Pharma A/S A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor
EP2172452A1 (en) 2005-05-03 2010-04-07 Ranbaxy Laboratories Limited Preparation of crystalline atorvastatin magnesium
CN101516842A (zh) 2006-05-11 2009-08-26 百康有限公司 阿托伐他汀镁晶型b4及其方法

Also Published As

Publication number Publication date
US8648109B2 (en) 2014-02-11
DK1957452T3 (da) 2010-07-26
ES2304335T3 (es) 2010-05-19
US8084488B2 (en) 2011-12-27
ATE466840T1 (de) 2010-05-15
JP2007137885A (ja) 2007-06-07
US20120059040A1 (en) 2012-03-08
DE602006014193D1 (de) 2010-06-17
TW200738624A (en) 2007-10-16
WO2007057755A1 (en) 2007-05-24
PT1957452E (pt) 2010-05-25
ES2304335T1 (es) 2008-10-16
US20100069459A1 (en) 2010-03-18
US20130131138A1 (en) 2013-05-23
US8383667B2 (en) 2013-02-26

Similar Documents

Publication Publication Date Title
AR058212A1 (es) Formas novedosas de acido (r-(r*, r* ))-2-(4-fluorofenil) - beta , delta- dihidroxi -5- (1- metiletil) -3-fenil-4- ( fenilamino) carbonil)-1h- pirrol -1- heptanoico magnesio
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
BRPI0510713A (pt) formas de sal de ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-diidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)ca rbonil]-1h-pirrol-1- heptanóico
AR057715A1 (es) Forma cristalina v de la agomelatina, un procedimiento para su preparacion, y composiciones farmaceuticas que la contienen
AR057713A1 (es) Forma cristalina iii de la agomelatina, un procedimiento para su preparacion, y las composiciones farmaceuticas que la contienen
MX2020007479A (es) Profármacos de ketamina, composiciones y usos de los mismos.
AR057714A1 (es) Nueva forma cristalina iv de la agomelatina, un procedimiento para su preparacion, y las composiciones farmaceuticas que la contienen
DOP2002000413A (es) Formas cristalinas de la sal de calcio del acido [r- (r*,r*)]-2-(4-fluorofenil)-b,o-dihidroxi-5-(1-metiletil) -3-fenil-4-[fenilamino)carbonil]-1h-pirrol-1- heptanoico (2:1)
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
CO5390079A1 (es) Compuestos heterociclicos novedosos que tienen actividades hipolipidemicas, hipocolesterolicas, proceso para su preparacion y composiciones farmaceuticas que los contienen y su uso en medicina
EA201270546A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
BRPI0512347B8 (pt) preparação da pregabalina e compostos relacionados
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
PE20061142A1 (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
CY1110900T1 (el) Χημικες ενωσεις
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
SV2007002526A (es) Diarilsulfona sulfonamidas y el uso de las mismas ref. p1018
PA8653401A1 (es) Nuevos inhibidores de hmg-co-a reductasa basados en pirazol
CL2004000732A1 (es) Compuestos derivados de oximas sustituidas y sus sales farmaceuticamente aceptables; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los contiene; y uso de los compuestos para el tratamiento del cancer.
ES2650604T3 (es) Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene
RS51944B (en) KRISTALNA BASE TRANS-1 - ((1R, 3S) -6-HLORO-3-PHENYLINDAN-1-IL) -3,3-DIMETILPIPERAZINE
DE602006019710D1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern
BRPI0519152A2 (pt) composto ou um sal ou derivado Éster farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, formulaÇÕes para tratar osteoporose e psorÍase, uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo, e, composiÇço farmacÊutica
AR064421A1 (es) Sintesis mejorada para la preparacion del acido[r-(r*,r*)]-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirrol-1-heptanoico o una sal farmaceuticamente aceptable del mismo,asi como de intermediarios usados en el procedimiento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure